NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting
Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research Meeting 2019, regarding the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer. TUSC2 is a tumor suppressor gene and the active agent in Genprex’s Oncoprex immunogene therapy. “Development of an improved humanized patient-derived xenograft, Hu-PDX, mouse model for evaluation of antitumor immune response in lung cancer,” was the title of the poster,…